The virus that caused the COVID 19 pandemic spread globally with an increase in deadly infections
in most countries, COVID-19 is caused by SARS-coronavirus-2 (SARS-CoV-2), which belongs to the
coronavirus family and is related to Severe Acute Respiratory Syndrome (SARS) andMiddle East
Respiratory Syndrome (MERS) virus. Structurally, SARS-CoV-2 is a virus wrapped with a positivesense single-stranded RNA genome. Proteins on the surface of the virion are responsible for
compromising the angiotensin-converting enzyme 2 (ACE2) receptor toenter susceptible host cells;
the initial infection is predominantly directed at the epithelial cells of the lungs and throat. Spray
microdroplets are thought to be the primary mode of viral transmission.
Patients hospitalized with severe or critical infections are treated with a selection of antiviral
agents (e.g. oseltamivir, lopinavir, ritonavir, remdesivir), combinations of antibiotics and/or
glucocorticoids depending on the clinical condition of patients, in addition to assisted ventilation
when breathing capacity is compromised [8–10]. With the current magnitude of contagious
infections and associated deaths caused by COVID-19, there is an urgency to employ additional
strategies to find treatment options capable of reducing deaths. Although there are encouraging
results with some therapies, there is still a need for other strategies, particularly specific
approaches such as nutritional inter- vention, inmunoenhancer, coronavirus-specific treatments
such as coronavirus protease inhibitors, etc. (trials are currently being con- ducted around the
world) [11,12].
Patients with COVID-19 develop clinical manifestations of high fever, cough, myalgia, dyspnoea with
or without diarrhea and pneu- monia, these manifestations are among the first recognized, every
day new symptoms are put associated with COVID-19 virus, but usually patients have
gastrointestinal problems such as nausea, vomiting, diar- rhea, abdominal pain, in addition to
shortness of breath, headache, sorethroat, colds, breathing problems, myalgia, nasal congestion
and inflammation of the mucous membranes that cover the inside of the sinuses and nasal
discharge, also in some cases occur injuries to the central nervous system.
The research focuses on the treatment of the symptoms of diseases related to the modification of
structural and functional proteins such as those that make up connective tissue, some of the
symptoms that these extracts mitigate are related to respiratory, cardiac, and metabolic diseases. ,
infectious, allergic and genetic.
The development provides a remedy and process for the activation of cellular molecules, mainly
proteins to reactivate their molecular activity, the active principles being a product that combines
refined plant extracts, as well as the solvents that balance these extracts.
The present invention is specifically directed to a pharmaceutical composition for the treatment of
symptoms produced in particular cases in diseases caused by damage to endothelial cells, such as
those caused by the SARS-CoV-2 virus, and other diseases where the diseases are affected. proteins
that make up endothelial cells, through a concentration of a product that combines fractionated
plant extracts as well as the solvents that balance these extracts; this to modify proteins and avoid
extreme damage to endothelial cells at a concentration that is effective in decreasing symptoms
present in a patient
The present development is also directed to a method for the treatment in humans suffering from
the side effects produced by vaccines caused to control the SARS-CoV-2 virus using a product that
combines plant extracts, as well as the solvents that balance these extracts, which comprises the
administration to humans effective doses of the composition of said product.
The present development is also aimed at a process of regeneration of lung tissue damaged by the
SARS-CoV-2 virus in humans, which comprises the administration to humans of the effective dose
of the product that combines plant extracts, as well as the solvents that balance these extracts, at a
concentration of the product that is effective for the regeneration of lung tissue damaged by the
SARS-CoV-2 virus. It also addresses a process to protect normal cells from the cytopathic effects of
viruses, which comprises administering effective doses to humans as well as the solvents that
balance these extracts, at a concentration of the product that is effective to protect against the
effects. cytopathic viruses.
Testing with Nasoil® began on April 20, 2020, and these observa- tions were completed on July 15,
2020. The effect of Nasoil® was studied in a total of 600 individuals of which 348 were men and 252
women, the average age was 44.27 years, with ages ranging from 20 to 78 years
The study population was divided into 6 (six) groups both by their conditions and the way in which
they evaluate their health condition, being people for preventive application, as well as co-adjuvant
to regain health, the preventive application has been carried out with people of nursing areas,
treating doctors from the COVID 19 area, people who cared at home for patients sick with SARS
CoV2 and people with regular to low exposure to infection; Of this population, 100% of the people
who were applied preventively maintained their health and did not manifest symptoms of any kind
in this regard, while 100% of the population that was applied as a co-adjuvant recovered their
health. In subsequent follow-up, with an applied population of approximately 15,000 people, there
is a record that 99.85% of the people have not manifested symptoms or complications with the
infection; 0.15% were positive and 100% of them recovered their normal condition in the short
term; While in treatment of positive people 99.87% recovered their health while 0.13% died, these
people being the ones who began to apply the present development being at level 6 of severity
(according to the scale of the Royal College London).
Regarding a pre-clinical analysis in conjoint application with various preventive vaccines to SARS
CoV2, it was found that the control group manifested in 79.62% some kind of side effect such as
fatigue, dizziness, weakness, headache among others, while the People who applied Nasoil Vir1 at
the same time as being vaccinated, 100% said they had no side effects, except for pain in the arm
due to the penetration of the needle, in addition, a better immune response was found in people who received the most Nasoil vaccine Vir1 measuring the formation of antibodies in the time after
the application of said vaccine.
Carlos Cuevas leads a small independent research group, in the area of research he has been
awarded by the INIFAP system in Mexico for research aimed at developing an oil fractioning system
as well as participating in research networks such as the International Network of Fruits and Flowers.
Vegetables and the Bioenergy Network, he also founds and chairs the Health Research and
Innovation Network, holds an academic doctorate from the Autonomous University of Madrid as
well as an honorary doctorate from the Mexico Chapter of the World University Cloister.
Some of the people on the research team are:
Marco Tulio Buenrostro Nava. Director of the master’s degree in protected agriculture. More than
40 published investigations on biotechnology and phytopathology issues.
Elisa Alejandra Ramírez. University merit medal. Various publications on biotechnology and health.
Blanca Isabel Mendoza Macías Basic research in biotechnology. Various publications on molecular
Raymundo René Rivas Cáceres Director of Molecular Biology at the Autonomous University of Cd
Juárez. Member of the National System of Researchers. CONACYT. Principal national researcher in
embryonic development and cell reproduction. State Prize for Science and Technology 2015